FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Sunday

 

Primary Progressive MS Patients May Soon Have Ocrevus as Treatment





























Results from the ORATORIO trial, exploring Ocrevus (ocrelizumab) for the treatment of primary progressive forms of multiple sclerosis (MS), showed that the drug stopped disease progression for more than two years in more patients than a placebo.
The findings, a highlight at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2016 Congress, Sept. 14-17, in London, raised hope that a treatment for patients with progressive MS may soon be available.

Xavier Montalban, a professor from the Vall d’Hebron University Hospital in Spain presented the study “Evaluation of no evidence of progression using composite disability outcome measures, in patients with primary progressive multiple sclerosis in the ORATORIO trial,” during a Sept. 16 session.

Ocrevus (produced by Roche) is an antibody targeting B-cells that express the CD20 molecule on its surface — a cell type researchers believe contributes significantly to neuronal damage.

The Phase 3 trial ORATORIO (NCT01194570) randomized 732 primary progressive MS patients to receive either 600 mg of Ocrevus as two 300 mg intravenous infusions 14 days apart (461 patients), or placebo, every 24 weeks (230 patients).

Patients were evaluated every 12 weeks. The treatment was continued for 120 weeks, or until patients experienced a predetermined number of disability progression events.

Researchers measured disability with the Expanded Disability Status Scale (EDSS), but patients are also tested with the 25-foot walk test and the 9-hole peg test.

The results showed that significantly more patients receiving Ocrevus had no evidence of progression at 120 weeks in comparison to placebo — 42.7 percent and 29.1 percent, respectively. A larger proportion of the treated patients with no disease activity also did better on the additional tests.

Ocrevus has also been analyzed in Phase 3 clinical trials for relapsing forms of MS.  Those positive results were also recently announced by Roche ECTRIMS 2016.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length

Labels:



Go to Newer News Go to Older News